echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > "Nature Genetics" Investigation of Lung Cancer without a Smoking History

    "Nature Genetics" Investigation of Lung Cancer without a Smoking History

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A genome analysis of lung cancer patients without a history of smoking found that most of these tumors are caused by the accumulation of mutations caused by natural processes in the body


    The research team said the new findings will help understand how people without a history of smoking develop lung cancer, and may guide the development of more precise clinical treatments


    Researchers including scientists from the National Institute of Environmental Health Sciences and other institutions published an article in the journal Nature Genetics entitled "Never Smokers Lung Cancer "Genomic and evolutionary classification of lung cancer in never smokers" paper, they concluded in the article, "Our findings indicate the development process of LCINS and possible new treatments


    The author points out that lung cancer is the leading cause of cancer-related deaths worldwide, and more than 2 million people worldwide are diagnosed with this disease every year


    Environmental risk factors, such as exposure to second-hand tobacco smoke, radon, air pollution, and asbestos, or previous lung disease, can explain some lung cancers in never-smokers, but scientists still don’t know most of the causes of these cancers


    In their large epidemiological study (part of the Sherlock-Lung Study), Landi and colleagues performed whole-genome sequencing to describe genomic changes in tumor tissues and matched 232 never-smokers (mainly European descent) of the normal organization, they were diagnosed with non-small cell lung cancer (NSCLC)



    As expected, because the study was limited to people who had never smoked, the researchers did not find any mutations that were previously associated with direct exposure to tobacco


    Genomic analysis also revealed three new subtypes of lung cancer in non-smokers.


    The dominant "piano" subtype has the least mutations; it seems to be related to the activation of progenitor cells, which are involved in the production of new cells


    The research team reported: “WGD is observed in more than 60% of LUAD among smokers.


    Landi said: "We are beginning to distinguish between subtypes that may have different prevention and treatment methods


    The research team concluded that at present, treatments for the most frequently recurring genomic changes in forte and mezzo forte have been provided or are being studied in clinical trials, that is, treatments for TP53 or MDM2-TP53 interactions and EGFR or ERBB2 mutations.


    The future direction of this research will be to study people of different ethnic backgrounds and geographic locations, whose lung cancer risk factor exposure history has been well described


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.